Kliniec Katarzyna, Snopkowska Aleksandra, Łyko Magdalena, Jankowska-Konsur Alina
Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, Poland.
Student Research Group of Experimental Dermatology, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, Poland.
J Clin Med. 2024 Jan 23;13(3):645. doi: 10.3390/jcm13030645.
Erythroderma is a condition characterized by erythema affecting at least 90% of the skin surface area. It can be caused by various underlying conditions. Due to nonspecific clinical and laboratory findings, determining the cause may pose a challenge. In the retrospective study, we identified 212 patients hospitalized for erythroderma in the Department of Dermatology, Venereology, and Allergology at Wroclaw Medical University between January 2012 and March 2022. Clinical, laboratory, and histopathological features, as well as the management of patients, were studied. The median age of adults was 61 years (IQR = 47-68). The most common causes of erythroderma were psoriasis ( = 49, 24.01%), followed by atopic dermatitis (AD) ( = 27, 13.23%), and cutaneous T-cell lymphomas (CTCL) ( = 27, 13.23%). Despite laboratory tests and histopathological examination, the etiology of erythroderma remained undetermined in 39 cases (19.12%). In 70.59% of patients, it was the first episode of erythroderma, while 29.41% experienced a recurrent episode. Regardless of the etiology of erythroderma, patients were most frequently treated with systemic antihistamines (146 cases, 71.57%) and systemic steroids (132 cases, 64.71%). Patients with idiopathic erythroderma constitute the greatest diagnostic and therapeutic challenge, requiring particularly thorough evaluation.
红皮病是一种以红斑累及至少90%皮肤表面积为特征的病症。它可由多种潜在病症引起。由于临床和实验室检查结果缺乏特异性，确定病因可能具有挑战性。在这项回顾性研究中，我们确定了2012年1月至2022年3月期间在弗罗茨瓦夫医科大学皮肤科、性病科和变态反应科因红皮病住院的212例患者。对患者的临床、实验室和组织病理学特征以及治疗情况进行了研究。成人的中位年龄为61岁（四分位间距 = 47 - 68岁）。红皮病最常见的病因是银屑病（n = 49，24.01%），其次是特应性皮炎（AD）（n = 27，13.23%）和皮肤T细胞淋巴瘤（CTCL）（n = 27，13.23%）。尽管进行了实验室检查和组织病理学检查，但仍有39例（19.12%）红皮病的病因未明确。70.59%的患者为红皮病首发，而29.41%的患者经历过复发。无论红皮病的病因如何，患者最常接受的治疗是全身性抗组胺药（146例，71.57%）和全身性类固醇（132例，64.71%）。特发性红皮病患者构成了最大的诊断和治疗挑战，需要进行特别彻底的评估。
